Quantus

NewAmsterdam Pharma

NAMS-US · Nasdaq
$27.79-2.35%
2026-07-31 close

NewAmsterdam Pharma — what's the grade? And what signals are flashing today?

Open the exact grade & valuation bands with Pro →
Loading chart…
Close
AI Insight

Why these signals fired — only backtest-proven edge, told honestly

Why this signalSignal guide

Moving-average alignment
No

No active signal.

Explore this stock further
Review signal, financial and filing context in chat
Explore in chat →

Strong-buy signal — the real recordrecord · not a prediction

Not this one stock, but every strong-buy pick we actually published (US market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)

Last 30 sessions
759 picks
Next-day win rate
58.8%
Avg next-day
+0.55%
vs market
+0.45%p

Beat the market on 57.6% of picks (each pick vs its own day’s market average).

Recent publish days (next-day win rate)
07-30 27.3%07-29 30.8%07-28 11.1%07-27 50%07-24 28.6%07-23 44.4%07-22 50%07-21 60%07-20 33.3%07-17 37.5%07-16 16.7%07-15 50%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.

Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.

Valuation Grades

Relative to 759 건강관리 peers · not investment advice

Pro unlocks the composite grade, 5 factors and sector rank · ₩19,900/mo

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 9.69
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
9.69
Beneish M-Score
1.74

Statistical manipulation-risk signal

Sloan accrual
-9.60%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

6/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score6/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -348%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업외손익 급변 (영업이익 대비 40% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

USAs of 2026-08-03

건강관리

This stock is in 건강관리: revenue rank 338 of 553, share 0%.

338 / 5530%revenue share

Who dominates this industry?

  1. 1CVS Health14.1%
  2. 2McKesson13.6%
  3. 3Cigna9.4%
  4. 4Cardinal Health8.4%
  5. 5Centene6.2%
  6. 6NewAmsterdam Pharma0%

Concentration

DistributedCR3 37.1%
HHI 642553 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
159.97
Direction
축소
Level
넓음
Years
22

Value lens

P90/P10
23.8
Median P/B
3.07
Level
넓음
n
467

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-386.9%
Interest coverage
-2.7x
Return on equity (ROE)
-31.9%

Operating margin −5pp

Operating loss
Interest coverageBase -2.7x adverse case -2.7x
Return on equity (ROE)Base -31.9% adverse case -32.2%

Revenue −15%

Interest coverage risk
Interest coverageBase -2.7x adverse case -2.3x
Return on equity (ROE)Base -31.9% adverse case -28.4%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -2.7x adverse case -2.6x
Return on equity (ROE)Base -31.9% adverse case -32.2%

Interest coverage limit

Already below the limit by 530.3pp

Interest coverage limit at an operating margin of 143.3%

Interest expense coverage threshold

Financials at a glance

NewAmsterdam Pharma's latest results and balance sheet. The bars track the last three periods.

Connections

AI-extracted related companies · for reference

Same theme
Cleveland ClinicAmerican Heart AssociationAmgenPrice comovement r=0.16 (1 year)
🔗 See in the full market map →

Recent filings

Filings for overseas stocks are on the way. For now we cover Korean stocks only.

Signal history (last ~2 years)

Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.

Golden cross×1
26-05-22-11.4%

“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.

Like these rules? Run them automatically.

Quantus turns rules like these into backtests and automated trading — same team, free to start.

Quantus Signal · live data · not investment advice · Privacy Policy